Figure 1

HDACis were potent inducers of the NKG2D-Ls MICA/B in humans. (a) Indicated cell lines were incubated with a panel of diverse DNA-damaging agents (gemcitabine (Gem), 2 μM; cytarabine (Ara-C), 10 μM; aphidicolin (Aph), 20 μM; bleomycin (Bleo), 30 μg/ml; and cisplatin (Cis), 10 μg/ml) and the HDACi TSA (trichostatin A, 250 nM) for 16 h. Flow cytometry (dead cells were excluded for analysis) was performed for surface expression of MICA/B. (b) MDA-231 cells were treated with a panel of different HDACis (TSA, 250 nM; CAY-10683, 5 μM; MS-275, 5 μM; scriptaid (SCR), 5 μM; SIRT1 inhibitor, 50 μM; and SIRT2 inhibitor, 50 μM) for 16 h and analyzed by FACS. Mean±s.d. of two or more independent experiments is indicated.